CN102933230B - 用于鼻内递送的方法和组合物 - Google Patents

用于鼻内递送的方法和组合物 Download PDF

Info

Publication number
CN102933230B
CN102933230B CN201180027287.1A CN201180027287A CN102933230B CN 102933230 B CN102933230 B CN 102933230B CN 201180027287 A CN201180027287 A CN 201180027287A CN 102933230 B CN102933230 B CN 102933230B
Authority
CN
China
Prior art keywords
virus
microns
vaccine
powder
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180027287.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102933230A (zh
Inventor
永田良一
治田俊二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Km Biomedical Co Ltd
Translational Research Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Shin Nippon Biomedical Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Shin Nippon Biomedical Laboratories Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to CN201710415508.1A priority Critical patent/CN107260689A/zh
Publication of CN102933230A publication Critical patent/CN102933230A/zh
Application granted granted Critical
Publication of CN102933230B publication Critical patent/CN102933230B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M3/00—Automatic or semi-automatic exchanges
    • H04M3/42—Systems providing special services or facilities to subscribers
    • H04M3/50—Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
    • H04M3/51—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
    • H04M3/5116—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/10—Connection setup
    • H04W76/15—Setup of multiple wireless link connections
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/18—Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Business, Economics & Management (AREA)
  • Signal Processing (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Emergency Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Marketing (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201180027287.1A 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物 Active CN102933230B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710415508.1A CN107260689A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32454210P 2010-04-15 2010-04-15
US61/324,542 2010-04-15
PCT/JP2011/002225 WO2011129120A1 (en) 2010-04-15 2011-04-15 Methods and compositions for intranasal delivery

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710415508.1A Division CN107260689A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN2013100510480A Division CN103126996A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Publications (2)

Publication Number Publication Date
CN102933230A CN102933230A (zh) 2013-02-13
CN102933230B true CN102933230B (zh) 2016-03-02

Family

ID=44798502

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180027287.1A Active CN102933230B (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN2013100510480A Pending CN103126996A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN201710415508.1A Pending CN107260689A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2013100510480A Pending CN103126996A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物
CN201710415508.1A Pending CN107260689A (zh) 2010-04-15 2011-04-15 用于鼻内递送的方法和组合物

Country Status (12)

Country Link
US (2) US9687536B2 (https=)
EP (2) EP2689785B1 (https=)
JP (5) JP5771626B2 (https=)
KR (3) KR102136036B1 (https=)
CN (3) CN102933230B (https=)
BR (1) BR112012026116A2 (https=)
CA (2) CA2796593C (https=)
CU (1) CU20120148A7 (https=)
ES (1) ES2874817T3 (https=)
RU (1) RU2012144612A (https=)
SG (1) SG184304A1 (https=)
WO (1) WO2011129120A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933230B (zh) * 2010-04-15 2016-03-02 株式会社新日本科学 用于鼻内递送的方法和组合物
US9795773B2 (en) 2011-12-16 2017-10-24 Indosys Limited Medicament unit dose cartridge and delivery device
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104208029B (zh) * 2013-05-30 2017-06-06 上海医药工业研究院 一种鼻用疫苗组合物粉体制剂及其制备方法
RU2720808C2 (ru) * 2013-09-03 2020-05-13 Джорджия Тек Рисёч Корпорейшн Термостабильные препараты вакцин и микроиглы
EP4008307A1 (en) * 2013-09-24 2022-06-08 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
JP2018533547A (ja) * 2015-09-16 2018-11-15 株式会社新日本科学 ワクチン組成物
GB201610628D0 (en) * 2016-06-17 2016-08-03 Mihranyan Albert New compositions
WO2018053524A1 (en) * 2016-09-19 2018-03-22 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11022115B2 (en) 2017-06-02 2021-06-01 Purdue Research Foundation Controlled variable delivery external gear machine
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
GB201713899D0 (en) 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
EP3847246A1 (en) * 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020123607A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
JP7660514B2 (ja) * 2019-02-15 2025-04-11 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生インフルエンザワクチン組成物及びその調製プロセス
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US11621604B2 (en) 2020-02-16 2023-04-04 Purdue Research Foundation Integrated electro-hydraulic machine
CA3175456A1 (en) * 2020-03-24 2021-09-30 Byung Chul Ahn Method of producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof
CN113583970B (zh) * 2021-07-29 2023-05-12 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN119866231A (zh) 2022-09-01 2025-04-22 锡拉坎岛有限公司 干粉药物递送装置
EP4630460A1 (en) * 2022-12-07 2025-10-15 Daocheng Zhu Formulation and use of a fusion protein
WO2024228212A1 (en) * 2023-05-01 2024-11-07 Biovet Private Limited Bio-lumpivaxin formulations and method of preparation thereof
WO2024246607A1 (en) * 2023-05-31 2024-12-05 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration
GB202403611D0 (en) 2024-03-13 2024-04-24 Therakind Ltd Improved multi-dose medicament delivery device
CN118924744A (zh) * 2024-07-29 2024-11-12 复旦大学 小分子抑制剂ha15在抗乙型肝炎病毒中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1893973A (zh) * 2003-12-17 2007-01-10 惠氏公司 产生储存稳定病毒及其免疫原性组合物的方法
CN101296705A (zh) * 2005-10-04 2008-10-29 阿尔克-阿贝洛有限公司 固体疫苗制剂
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5547594A (en) * 1992-11-03 1994-05-24 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CN1193745C (zh) 2001-02-27 2005-03-23 国家医药管理局上海医药工业研究院 一种鼻用鲑降钙素粉末吸入剂及制备方法
CN1607941A (zh) 2001-11-19 2005-04-20 贝克顿迪肯森公司 粒状药物组合物
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US20060292173A1 (en) 2004-12-13 2006-12-28 Macadam Donald H Multibacterial vaccines and uses thereof
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
ITMI20061117A1 (it) 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20080226729A1 (en) 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
SG10202012986SA (en) * 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009006299A2 (en) 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
ES2615390T3 (es) * 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP5491119B2 (ja) 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
AU2012244074B2 (en) 2010-04-15 2015-01-15 Km Biologics Co., Ltd. Methods and compositions for intranasal delivery
CN102933230B (zh) 2010-04-15 2016-03-02 株式会社新日本科学 用于鼻内递送的方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1893973A (zh) * 2003-12-17 2007-01-10 惠氏公司 产生储存稳定病毒及其免疫原性组合物的方法
CN101296705A (zh) * 2005-10-04 2008-10-29 阿尔克-阿贝洛有限公司 固体疫苗制剂
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗

Also Published As

Publication number Publication date
CU20120148A7 (es) 2013-01-30
JP6827488B2 (ja) 2021-02-10
JP2013126989A (ja) 2013-06-27
US20130273120A1 (en) 2013-10-17
KR20130083376A (ko) 2013-07-22
EP2689785B1 (en) 2021-05-19
CN103126996A (zh) 2013-06-05
JP2019104751A (ja) 2019-06-27
SG184304A1 (en) 2012-11-29
US9687536B2 (en) 2017-06-27
RU2012144612A (ru) 2014-05-20
BR112012026116A2 (pt) 2016-06-28
JP5771626B2 (ja) 2015-09-02
CN107260689A (zh) 2017-10-20
KR102136036B1 (ko) 2020-07-20
CA2993242A1 (en) 2011-10-20
CN102933230A (zh) 2013-02-13
US20130129781A1 (en) 2013-05-23
WO2011129120A1 (en) 2011-10-20
CA2993242C (en) 2020-12-15
EP2558120A1 (en) 2013-02-20
KR101960102B1 (ko) 2019-03-19
JP2016006119A (ja) 2016-01-14
CA2796593C (en) 2020-12-15
JP2017186377A (ja) 2017-10-12
JP2013523602A (ja) 2013-06-17
CA2796593A1 (en) 2011-10-20
KR20130064741A (ko) 2013-06-18
EP2689785A1 (en) 2014-01-29
EP2558120A4 (en) 2013-08-28
KR20190028555A (ko) 2019-03-18
US10463723B2 (en) 2019-11-05
ES2874817T3 (es) 2021-11-05

Similar Documents

Publication Publication Date Title
CN102933230B (zh) 用于鼻内递送的方法和组合物
JP7082703B2 (ja) ワクチン組成物
JP2011514337A (ja) 糖ガラス化ウィルス様粒子（ｖｌｐ）
CN106456585B (zh) 疫苗组合物
Perrie et al. Recent developments in particulate-based vaccines
AU2012244077B2 (en) Methods and compositions for intranasal delivery
US20220325250A1 (en) Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
Hendy Improved Delivery of a Broadly Active Influenza Subunit Vaccine
WO2025029323A1 (en) Compositions, methods, and uses for polynucleotide formulations for drying and prolonged storage
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RE

Effective date: 20130130

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130130

Address after: Kagoshima County, Japan

Applicant after: Translational Res Ltd.

Applicant after: Common Financial Group Legal Person Chemical and Serum Therapy Research Institute

Address before: Kagoshima County, Japan

Applicant before: Translational Res Ltd.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190115

Address after: Kagoshima County, Japan

Co-patentee after: KM Biomedical Co., Ltd.

Patentee after: Translational Res Ltd.

Address before: Kagoshima County, Japan

Co-patentee before: Common Financial Group Legal Person Chemical and Serum Therapy Research Institute

Patentee before: Translational Res Ltd.